Risk of litigation and regulatory action due to dispensing errors or defects in dispensed medicines
First written in FY2017. 10 of 19 entries say "Restated". Latest entry: FY2027-H1.
Sundrug moved to the "Worse" side of this theme in 2022.
The whole theme swung hardest in 2022: 1 of 7 companies on the "Worse" side.
8 other companies' latest entry also says "Restated".
- FY2027-H1RestatedAnnual report
「No new business or other risks arose during the six months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company stated that there have been no material changes regarding the risk of litigation and regulatory action due to dispensing errors or defects in dispensed medicines. - FY2026WorsenedAnnual report
「The Group’s pharmacy services, offered at 249 of its stores, are expected to handle a further increase in prescriptions as the separation of prescribing and dispensing progresses. There is a possibility of future litigation or regulatory action due to defects in dispensed medicines, dispensing errors or other causes」
The number of stores offering pharmacy services increased from 210 to 249, expanding exposure to the risks of litigation and regulatory action associated with dispensing errors. - FY2025WorsenedAnnual report
「The Group’s pharmacy services, offered at 210 of its stores, are expected to handle a further increase in prescriptions as the separation of prescribing and dispensing progresses. There is a possibility of future litigation or regulatory action due to defects in dispensed medicines, dispensing errors or other causes」
The number of stores offering pharmacy services increased from 187 to 210, expanding exposure to the risks of dispensing errors, litigation and regulatory action associated with rising prescription volumes. Measures involving audit check cameras, consideration of introducing dispensing robots and pharmacy liability insurance remain in place. - FY2025-H1RestatedAnnual report
「No new business or other risks arose during the interim consolidated accounting period. In addition, there were no significant changes to the business and other risks described in the previous fiscal year's Annual Securities Report.」
The company stated that there have been no material changes to existing risks, including the risk of litigation and regulatory action due to dispensing errors or defects in dispensed medicines. - FY2024WorsenedAnnual report
「The Group’s pharmacy services, offered at 187 of its stores, are expected to handle a further increase in prescriptions as the separation of prescribing and dispensing progresses. There is a possibility of future litigation or regulatory action due to defects in dispensed medicines, dispensing errors or other causes」
The number of stores offering pharmacy services increased from 147 to 187, expanding exposure to the risks of dispensing errors, litigation and regulatory action associated with rising prescription volumes. The company also described measures involving audit check cameras, consideration of introducing dispensing robots and pharmacy liability insurance. - FY2024-Q3RestatedAnnual report
「No new business or other risks arose during the nine months ended 31 December. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes to existing risks, including the risk of litigation and regulatory action due to dispensing errors or defects in dispensed medicines. - FY2023WorsenedAnnual report
「The Group’s pharmacy services, offered at 147 of its stores, are expected to handle a further increase in prescriptions as the separation of prescribing and dispensing progresses. Accordingly, there is a possibility of future litigation or regulatory action due to defects in dispensed medicines, dispensing errors or other causes」
The number of stores offering pharmacy services increased from 115 to 147, expanding exposure to the risks of dispensing errors, litigation and regulatory action associated with rising prescription volumes. Measures involving audit check cameras, consideration of dispensing robots and insurance coverage remain in place. - FY2023-Q2RestatedAnnual report
「No new business or other risks arose during the six months ended 30 September. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes to existing risks, including the risk of litigation and regulatory action due to dispensing errors or defects in dispensed medicines. - FY2022WorsenedAnnual report
「The Group’s pharmacy services, offered at 115 of its stores, are expected to handle a further increase in prescriptions as the separation of prescribing and dispensing progresses. Accordingly, there is a possibility of future litigation or regulatory action due to defects in dispensed medicines, dispensing errors or other causes」
The number of stores offering pharmacy services increased from 103 to 115, expanding exposure to the risks of dispensing errors, litigation and regulatory action associated with rising prescription volumes. The company also described audit check cameras, plans to consider introducing dispensing robots and insurance coverage. - FY2022-Q2RestatedAnnual report
「During the second quarter consolidated cumulative period, there were no newly arising business or other risks. In addition, there were no significant changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company stated that there have been no material changes regarding the risk of litigation and regulatory action due to dispensing errors or defects in dispensed medicines. - FY2022-Q1RestatedAnnual report
「No new business or other risks arose during the three months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company stated that there have been no material changes regarding the risk of litigation and regulatory action due to dispensing errors or defects in dispensed medicines. - FY2021WorsenedAnnual report
「The Group’s pharmacy services, offered at 103 of its stores, are expected to handle a further increase in prescriptions as the separation of prescribing and dispensing progresses. Accordingly, there is a possibility of future litigation or regulatory action due to defects in dispensed medicines, dispensing errors or other causes」
The number of stores offering pharmacy services increased to 103, expanding exposure to the risks of dispensing errors, litigation and regulatory action associated with rising prescription volumes. The company also described plans to consider introducing audit check cameras and dispensing robots. - FY2020-Q1RestatedAnnual report
「No new business or other risks arose during the three months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes to existing risks, including the risk of litigation and regulatory action due to dispensing errors or defects in dispensed medicines. - FY2019WorsenedAnnual report
「The Group’s pharmacy services, offered at 86 of its stores, are expected to handle an increasing number of prescriptions as the separation of prescribing and dispensing progresses. However, there is a possibility of future litigation or regulatory action due to defects in dispensed medicines, dispensing errors or other causes」
The number of stores offering pharmacy services increased from 74 to 86, and prescriptions are expected to increase. The company continues to disclose the risk of litigation and regulatory action arising from dispensing errors. - FY2019-Q3RestatedAnnual report
「No new business or other risks arose during the nine months ended 31 December. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes to existing business and other risks, including the risk of litigation and regulatory action due to dispensing errors or defects in dispensed medicines. - FY2019-Q1RestatedAnnual report
「No new business or other risks arose during the three months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of litigation and regulatory action due to dispensing errors or defects in dispensed medicines. - FY2018WorsenedAnnual report
「The Group’s pharmacy services, offered at 74 of its stores, are expected to handle an increasing number of prescriptions as the separation of prescribing and dispensing progresses. The Group is working through its pharmacy division to improve dispensing-related expertise and pharmaceutical knowledge across the Group, and provides pharmacy services with the utmost care under a comprehensive management system to prevent dispensing errors. As a risk-management measure, all stores are covered by pharmacy liability insurance.」
The number of stores offering pharmacy services increased from 62 in FY2017 to 74, and an increase in prescriptions handled is expected. The company also described measures including improvements in expertise and knowledge, its management system and liability insurance. - FY2018-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter of the current consolidated fiscal year. There have also been no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes to existing business and other risks, including the risk of litigation and regulatory action due to dispensing errors or defects in dispensed medicines. - FY2017First statedAnnual report
「The Group’s pharmacy services, offered at 62 of its stores, are expected to handle an increasing number of prescriptions as the separation of prescribing and dispensing progresses.」
The company noted the possibility of litigation, regulatory action and reputational damage arising from defects in dispensed medicines or dispensing errors as pharmacy services expand. Pharmacy services are offered at 62 stores.